<DOC>
	<DOCNO>NCT02096289</DOCNO>
	<brief_summary>This Phase I trial investigate safety use thioridazine addition cytarabine elderly patient relapse refractory Acute Myeloid Leukemia .</brief_summary>
	<brief_title>Safety Study Thioridazine Combination With Cytarabine Treat Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thioridazine</mesh_term>
	<criteria>Have diagnosis AML accord WHO Classification1 AML refractory relapse ( require least 5 % leukemic blast bone marrow , regardless presence feature new recurrent dysplastic change extra medullary disease ) accord follow definition : Relapsed ( define ≥ 5 % leukemic blast bone marrow ) three month receive three prior induction regimen . Refractory ( define ≥ 5 % leukemic blast bone marrow ) one prior induction regimen ( defined failure achieve CR CRi follow induction therapy ) . 55 year age old . Receiving systemic antileukemic therapy ( standard investigational ) . Having receive two prior chemotherapy line AML . Induction/consolidation therapy bone marrow transplant consider line therapy . Having receive previous AML therapy within four week first dose study drug , exception hydroxyurea . Clinical evidence suggestive CNS involvement leukemia unless lumbar puncture confirm absence leukemic blast CSF . Acute promyelocytic leukemia . An ECOG performance status 3 . Inadequate renal function ( i.e. , estimate GFR &lt; 60 mL/min/1.73m2 ) . Inadequate hepatic function ( i.e. , serum bilirubin &gt; 1.5×ULN ; AST , ALT alkaline phosphatase &gt; 2.5×ULN ) . Presence acute chronic GVHD . Presence systemic fungal , bacterial , viral infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Having severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver organ system may place patient undue risk undergo induction therapy . Diagnosed condition prolong QT interval ( e.g. , long QT syndrome ) QTc interval ≥ 470ms male , ≥ 480ms female . Left ventricular ejection fraction le 45 % . History uncontrolled cardiac arrhythmia . Known severe hypotensive hypertensive heart disease . Prior malignancy , unless patient diseasefree least five year follow curative intent therapy , follow exception : Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , definitive treatment condition complete ; patient organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value hormonal therapy initiate radical prostatectomy perform . Known HIV positivity . Known pregnancy lactate female . Presence psychiatric disorder would interfere consent , study participation , followup . Unable provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Relapsed Acute Myeloid Leukemia</keyword>
	<keyword>Refractory Acute Myeloid Leukemia</keyword>
	<keyword>Thioridazine</keyword>
	<keyword>Phase I</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>